Healthcare Equipment and Supplies
Company Overview of ArraVasc Limited
ArraVasc Limited designs, manufactures, and markets devices for interventional clinicians. The company develops catheters; and novel access technologies for the treatment of coronary artery disease. It focuses on peripheral vascular diseases. The company supplies its products to strategic OEM partners through distributors. ArraVasc Limited was formerly known as Cappella Medical Devices Limited and changed its name to ArraVasc Limited in May 2014. The company was incorporated in 2005 and is based in Galway, Ireland. Cappella Medical Devices Limited operates as a subsidiary of Cappella Inc.
Ballybrit Business Park
Founded in 2005
Key Executives for ArraVasc Limited
Chief Executive Officer and Director
Chief Financial Officer and Director
Vice President of Commercial Operations
Compensation as of Fiscal Year 2014.
ArraVasc Limited Key Developments
Cappella Medical Devices Limited Announces Long Term Follow-Up Results for Sideguard(R) Technology
Oct 22 12
Cappella Medical Devices Limited announced the multicenter long term follow up results for its innovative Sideguard(R) coronary sidebranch stent. Long term follow up data on the Sideguard stent was obtained from 399 patients from the United Kingdom, Germany, and Italy. The MACE rate was: 3.7% (30 day F/U), 7.1% (6 mo F/U) and 10.2% (1 year F/U) comparing favourably with existing standard practice. This data represents the multicenter clinical experience to date with the Sideguard technology. The Sideguard was developed to protect the ostium of the sidebranch offering interventional cardiologists a dynamic, effective, and easy-to-use solution in the treatment of bifurcation disease. Results from this multicenter experience have confirmed that preservation of the sidebranch of diseased coronary arteries by protecting the ostium has clear long term benefits when compared to existing standard practice of provisional and two-stent procedures. Up to 30% of all PCI patients have bifurcation disease yet there has not been one proven dedicated treatment solution. Treating these patients has always been a challenge for physicians due to the complex anatomy of the coronary sidebranch. Gary Brogan, VP of Regulatory and Clinical Affairs at Cappella, stated, "Up until now, physicians have been forced to treat the bifurcation with either two stents that weren't intended for this use, or one main vessel stent that has limitations in terms of ostial protection and sidebranch preservation. The provisional and two-stent techniques used all involve manipulating the straight DES stent struts in an attempt to provide clear access into the sidebranch. Data is now being presented documenting the negative flow dynamic and shear stress issues of floating stent struts. This long term follow up data validates the unique advantages of the Cappella Sideguard technology even when compared to existing DES treatment options.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries